B. Riley Comments on Abacus Life’s Q1 Earnings (NASDAQ:ABL)

Abacus Life, Inc. (NASDAQ:ABL) – Research analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Abacus Life in a report released on Monday, November 25th. B. Riley analyst M. Howlett forecasts that the company will post earnings per share of $0.25 for the quarter. B. Riley currently has a “Buy” rating and a $17.00 target price on the stock. The consensus estimate for Abacus Life’s current full-year earnings is $0.64 per share. B. Riley also issued estimates for Abacus Life’s Q2 2025 earnings at $0.26 EPS, Q3 2025 earnings at $0.27 EPS, Q4 2025 earnings at $0.27 EPS, FY2025 earnings at $1.05 EPS, Q1 2026 earnings at $0.36 EPS, Q2 2026 earnings at $0.38 EPS, Q3 2026 earnings at $0.40 EPS and FY2026 earnings at $1.56 EPS.

Other equities analysts also recently issued reports about the company. Northland Securities assumed coverage on Abacus Life in a research note on Thursday, October 24th. They issued an “outperform” rating and a $13.50 target price for the company. B. Riley Financial restated a “buy” rating and set a $16.00 price objective on shares of Abacus Life in a research note on Friday, August 30th. Northland Capmk upgraded shares of Abacus Life to a “strong-buy” rating in a research report on Thursday, October 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $13.00 price objective (up previously from $12.00) on shares of Abacus Life in a report on Friday, November 8th. Finally, TD Cowen started coverage on shares of Abacus Life in a research report on Wednesday, August 7th. They issued a “buy” rating and a $14.00 target price for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $14.70.

Abacus Life Price Performance

NASDAQ ABL opened at $7.82 on Wednesday. Abacus Life has a one year low of $6.56 and a one year high of $13.25. The company has a 50-day simple moving average of $9.26 and a 200-day simple moving average of $9.78. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.65.

Abacus Life (NASDAQ:ABL) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.20 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.06. The business had revenue of $28.15 million during the quarter, compared to the consensus estimate of $26.08 million. Abacus Life had a positive return on equity of 12.88% and a negative net margin of 11.65%. During the same period last year, the firm earned $0.01 earnings per share.

Institutional Trading of Abacus Life

A number of large investors have recently added to or reduced their stakes in the business. Richard W. Paul & Associates LLC boosted its position in shares of Abacus Life by 4.8% in the 2nd quarter. Richard W. Paul & Associates LLC now owns 30,448 shares of the company’s stock valued at $263,000 after purchasing an additional 1,401 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in shares of Abacus Life in the second quarter worth approximately $9,909,000. Principal Financial Group Inc. acquired a new stake in shares of Abacus Life during the second quarter valued at approximately $8,105,000. Stieven Capital Advisors L.P. purchased a new stake in shares of Abacus Life in the 2nd quarter valued at approximately $2,811,000. Finally, Levin Capital Strategies L.P. acquired a new position in Abacus Life in the 2nd quarter worth approximately $130,000.

Insider Activity at Abacus Life

In other news, CEO Jay J. Jackson sold 2,031,250 shares of the business’s stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $8.00, for a total value of $16,250,000.00. Following the sale, the chief executive officer now owns 10,562,000 shares of the company’s stock, valued at approximately $84,496,000. The trade was a 16.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Matthew Ganovsky sold 156,250 shares of the firm’s stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $8.00, for a total value of $1,250,000.00. Following the transaction, the insider now directly owns 10,847,047 shares of the company’s stock, valued at $86,776,376. This represents a 1.42 % decrease in their position. The disclosure for this sale can be found here. 79.20% of the stock is currently owned by insiders.

Abacus Life Company Profile

Abacus Life, Inc operates as an alternative asset manager specializing in life insurance products. It purchases life insurance policies from consumers seeking liquidity and manages policies over time via trading, holding, and/or servicing. The company was founded in 2004 and is based in Orlando, Florida.